urapidil innehaollande farmaceutisk komposition och dess framstaellning.

摘要

A sustained-release pellet pharmaceutical form for urapidil is described, which besides urapidil contains an excess of a pharmacologically acceptable aliphatic dicarboxylic acid and is provided with an enteric-resistant coating. The novel pharmaceutical form allows the daily single administration of urapidil and is distinguished by a good bioavailability.